John Carroll

It all started to look seriously bad when my legs began to swell up, which I initially — stupidly — shrugged off. By the time it became apparent that my kidneys had ...

Some, though certainly not all, chief indicators of biotech business activity are pointed shakily north as we head into a critical Q4. But biotech shows signs of taking another step ...

A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's nomination as FDA chief has eased some worries, while Robert F. Kennedy Jr.'s potential HHS leadership raises concerns. Most executives expect major policy changes, particularly regarding vaccines, though Makary's appointment from Johns Hopkins has provided some optimism for stability in drug development.

The Endpoints 100 is our semi-regular survey of biotech and pharma executives.

It’s time for one last look at the biotech numbers for 2024. And you might be surprised by some bullish charts below — especially if you zero in on deal numbers ...

Last week at JP Morgan, BioMarin CEO JJ Bienaimé laid out his thoughts on pricing the leading gene therapy for hemophilia A at $2 million to $3 million a shot. Payers would support that, he said, putting the biotech on track to launching a treatment that could top the price

RA Capital leads as most active venture player in private biotech rounds through 2024, with ARCH participating in fewer but larger rounds, per DealForma analysis.

Step back from the multitude of details that go into every big pharma pipeline, and you'll see the influence that blockbusters have on the entire field. These days, making your ...

The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry yearning for better times. Talk to CEOs these ...

Biotech execs express concerns over FDA changes, NIH cuts, and Trump's tariffs. Industry confidence low amid poor funding environment and dead IPO market in 2025.